Open AccessGenetics and biomarker in bladder cancer for optimized clinical decision-making and improved outcomes
Author(s) -
Michael Rink
Publication year - 2017
Publication title -
translational andrology and urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.721
H-Index - 27
eISSN - 2223-4691
pISSN - 2223-4683
DOI - 10.21037/tau.2017.12.05
Subject(s) - biomarker , bladder cancer , medicine , clinical decision making , biomarker discovery , computational biology , cancer , bioinformatics , intensive care medicine , biology , genetics , gene , proteomics
Urothelial carcinoma is the second most common urological malignancy after prostate cancer and with approximately estimated 79,000 newly diagnosed cases and 16,800 deaths in the United states in 2017 a significant burden of morbidity and mortality (1).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom